Key result
A novel PRRSV replicon vector containing FMDVP12A3C successfully expressed FMDV structural protein and PRRSV N protein in vitro, demonstrating potential for future FMD vaccine development.
A novel PRRSV replicon vector successfully expressed FMDV structural proteins in vitro, suggesting its potential as a vector system for foot-and-mouth disease vaccine development.
Supports PRRSV replicon vectors for FMD vaccine research; leaves open in vivo efficacy and clinical translation.
PURPOSE: Foot-and-mouth disease (FMD) is an economically important global animal disease. To control FMD virus (FMDV) outbreaks, a lot of different novel approaches have been attempted. In this study, we proposed a novel porcine reproductive and respiratory syndrome virus (PRRSV) as a replicon vector to express FMDV structural protein. MATERIALS AND METHODS: PRRSV infectious clone (PRRSVK418DM) was used to develop an expression vector through the reverse genetic manipulation of PRRSV; FMDVP12A3C gene of serotype O was synthesized and used for an antigen. MARC-145 cells (African green monkey kidney epithelial cell line) were used for electroporation mediated transfection. The transfection or the expression of P12A3C and N protein of PRRSV was analyzed by either replicon containing PRRSV alone or by co-infection of helper PRRSV. RESULTS: We constructed PRRSVK418DM replicon vector containing FMDVP12A3C, and genome sequences were confirmed by subsequent sequence analysis. In vitro expression of P12A3C and PRRSV N protein was confirmed by immunofluorescence antibody assay using antibodies specific for PRRSV N protein (anti-PRRSV N MAb), FMDV-VP1 (anti-VP1 MAb). CONCLUSION: The results indicate that PRRSV replicon vector can be a promising novel vector system to control FMDV and useful for vaccine development in the future.
No takes yet. Share an insight, caveat, or question.
Jeeva et al. (2014) studied Foot-and-mouth disease. PRRSV replicon vector containing FMDVP12A3C was evaluated on In vitro expression of P12A3C and PRRSV N protein. A novel PRRSV replicon vector containing FMDVP12A3C successfully expressed FMDV structural protein and PRRSV N protein in vitro, demonstrating potential for future FMD vaccine development.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: